VEGFA and age-related macular degeneration: The substantial role of VEGF in AMD is sustained by the fact that new therapies for wet AMD are mainly focused on VEGF inhibition although anti-VEGF therapies display significant limitations due to their limited half-life and subsequent treatment costs (Chakravarthy et al., 2022; Sarkar et al., 2022), Therefore, alternative strategies aiming at preventing or delaying the disease progression represents one of the current goals for the management of AMD.